Athira Pharma, Inc.
ATHA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3 | $4 | $4 | $9 |
| G&A Expenses | $4 | $4 | $5 | $6 |
| SG&A Expenses | $4 | $4 | $5 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | $0 |
| Operating Expenses | $7 | $7 | $9 | $16 |
| Operating Income | -$7 | -$7 | -$10 | -$16 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $1 |
| Pre-Tax Income | -$7 | -$7 | -$9 | -$15 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$7 | -$9 | -$15 |
| % Margin | – | – | – | – |
| EPS | -1.68 | -1.78 | -2.3 | -3.9 |
| % Growth | 5.6% | 22.6% | 41% | – |
| EPS Diluted | -1.68 | -1.78 | -2.3 | -3.9 |
| Weighted Avg Shares Out | 4 | 4 | 4 | 4 |
| Weighted Avg Shares Out Dil | 4 | 4 | 4 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$7 | -$9 | -$15 |
| % Margin | – | – | – | – |